FDA Cites Immunogenicity Concerns In “Not Approvable” Letter For Momenta/Sandoz’s Lovenox Generic
Firm is “confident” no immunogenicity differences will arise, Momenta CEO Wheeler says.
Firm is “confident” no immunogenicity differences will arise, Momenta CEO Wheeler says.